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Abstract
Background
Little is known about how early postoperative complications after oesophagectomy for can-
cer influence healthcare utilisation in the long-term. We hypothesised that these complica-
tions also increase healthcare utilisation long after the recovery period.
Methods
This was a prospective, nationwide Swedish population-based cohort study of patients who
underwent curatively intended oesophagectomy for cancer in 2001-2005 and survived at
least 1 year postoperatively (n = 390). Total days of in-hospitalisation, number of hospitali-
sations and number of visits to the outpatient clinic within 5 years of surgery were analysed
using quasi-Poisson models with adjustment for patient, tumour and treatment characteris-
tics and are expressed as incidence rate ratios (IRR) and 95% confidence intervals (CI).
Results
There was an increased in-hospitalisation period 1-5 years after surgery in patients with more
than 1 complication (IRR 1.5, 95% CI 1.0-2.4). The IRR for the number of hospitalisations by
number of complications was 1.1 (95%CI 0.7-1.6), and 1.2 (95%CI 0.9-1.6) for number of
outpatient visits in patients with more than 1 complication. The IRR for in-hospitalisation
period 1-5 years following oesophagectomy was 1.8 (95%CI 1.0-3.0) for patients with anas-
tomotic insufficiency and 1.5 (95%CI 0.9-2.5) for patients with cardiovascular or cerebrovas-
cular complications. We found no association with number of hospitalisations (IRR 1.2, 95%
CI 0.7-2.0) or number of outpatient visits (IRR 1.3, 95% CI 0.9-1.7) after anastomotic insuffi-
ciency, or after cardiovascular or cerebrovascular complications (IRR 1.2, 95% CI 0.7-1.9)
and (IRR 1.1, 95% CI 0.8-1.5) respectively.
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Conclusion
This study showed an increased total in-hospitalisation period 1-5 years after oesophagect-
omy for cancer in patients with postoperative complications, particularly following
anastomotic insufficiency.
Introduction
The incidence of oesophageal cancer is increasing in many Western countries.[1] The curative-
ly intended treatment for oesophageal cancer typically includes oesophagectomy, an extraordi-
narily extensive procedure which holds a 30% to 50% risk of serious postoperative
complications, and a 5% risk of in-hospital mortality.[1,2] The overall prognosis for patients
with oesophageal cancer is slowly improving, but the relative overall 5-year survival is still only
10–15% and the postoperative 5-year survival 30–55%.[2] Major surgical complications nega-
tively influence survival, reduce quality of life,[3,4] and increase the risk of several symptoms
persisting up to 5 years following surgery.[5,6] It is relevant for healthcare administrators and
healthcare professionals to understand patterns in healthcare utilisation, which might help pre-
dict future costs and healthcare consumption.[7] Studies on cancer survivorship and healthcare
utilisation show that compared to the background population, cancer patients more often visit
their medical specialist and are more often admitted to the hospital.[7,8,9,10] In-hospitalisa-
tion results in the greatest cost allocation for diseases in general.[7] Length of stay at the time
of surgery is obviously longer for patients with complications,[11,12] but any influence of early
postoperative complications on healthcare utilisation from a longer-term perspective is un-
known. Therefore, the main aim of this study was to assess the influence of early major postop-
erative complications after oesophagectomy for cancer on postoperative healthcare utilisation
1 to 5 years after surgery by using a prospective population-based cohort, taking into account
any influence of major patient and tumour characteristics.
Materials and Methods
Design
This was a nationwide Swedish prospective and population-based cohort study; the cohort has
been described in more detail elsewhere.[13,14] In brief, the entire cohort consisted of 616 pa-
tients (90% of all those eligible) who underwent oesophageal resection for cancer of the oe-
sophagus or oesophago-gastric junction with curative intent during the period April 2001 to
December 2005 in Sweden.[15] The follow-up period was set at a maximum of 5 years to assess
healthcare utilisation related to the oesophageal cancer or its treatment, rather than healthcare
use for other reasons (although all healthcare utilisation during the study period was evaluat-
ed). This study was organised through collaboration in Sweden between 174 hospital depart-
ments involved in the diagnosis or treatment of these patients.[14] Exclusions were made for
unknown histology (n = 9) and death within 1 year of surgery (n = 217), since our main interest
was long-term healthcare utilisation and healthcare utilisation is expected to be disproportion-
ally increased in patients who die shortly after surgery. Data were collected on patient, tumour
and treatment characteristics from the review of medical records from all Swedish hospitals
that performed oesophagectomies during the study period. This included age, sex, comorbidity,
histological tumour type and tumour stage, as well as the exposure data on pre-defined compli-
cations (presented below).[14] Outcome data on hospitalisation dates, days of in-
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hospitalisation and visits to the outpatient clinic of the study cohort members following the ini-
tial hospital stay during surgery were collected from the nationwide complete Swedish Patient
Registry.
Exposures
The study exposure was pre-defined significant complications within 30 days of surgery. The
complications were selected by a group of experienced Swedish oesophageal surgeons and re-
searchers prior to the inclusion phase of the cohort.[14,16] The following complications with
these definitions were included: 1) major postoperative bleeding (exceeding 2L or requiring re-
operation), 2) anastomotic insufficiency (clinically obvious and radiologically or endoscopi-
cally verified), 3) necrosis of the substitute (clinically significant ischemia entailing perforation
or ulceration), 4) intra-abdominal abscesses (causing clinical symptoms or radiologically veri-
fied), 5) intra-thoracic abscesses (causing clinical symptoms or radiologically verified), 6) sepsis
(causing clinical symptoms and positive bacterial culture in the blood), 7) wound infection
(causing clinical symptoms and requiring intervention), 8) anastomotic leakage (causing clini-
cal symptoms and verified by radiology or endoscopy), 9) kidney failure (requiring renal re-
placement therapy), 10) respiratory insufficiency (requiring re-intubation and mechanical
ventilation), 11) liver insufficiency (causing jaundice), 12) recurrent laryngeal nerve paralysis
(ascertained by laryngeal inspection), 13) pneumonia (proven by infiltrate on radiology and
causing clinical symptoms with fever, coughing or dyspnoea), 14) lung embolism (radiological-
ly verified and requiring treatment), 15) other embolism (radiologically verified and requiring
treatment), 16) deep venous thrombosis (clinically or radiologically verified and requiring
treatment), 17) ileus (radiologically verified and requiring surgery), 18) injured ductus thoraci-
cus (with severe lymph leakage requiring drainage for more than 7 days or reoperation), 19)
acute myocardial infarct (clinical symptoms and verified with electrocardiogram or heart en-
zymes), 20) atrial fibrillation (requiring treatment and new-onset atrial fibrillation), 21) cere-
brovascular infarct (verified by computerised tomography), 22) strictures of anastomosis
(requiring endoscopic intervention), and 23) gastric perforation (requiring surgical
intervention).
The main exposure, number of complications, was categorised into three groups: 1) no com-
plications, 2) 1 complication, or 3) more than 1 complication. The secondary exposures were
two specific groups of complications, which were expected to be associated with an increased
healthcare utilisation in the long-term, namely cardiovascular or cerebrovascular complica-
tions (including embolism, deep venous thrombosis, myocardial infarction, atrial fibrillation
and cerebrovascular infarction) and anastomotic insufficiency (also including necrosis of the
substitute or anastomotic leakage). The group of cardiovascular or cerebrovascular complica-
tions was categorised in 3 groups, 1) no complications, 2) complications other than cardiovas-
cular or cerebrovascular complications, or 3) cardiovascular or cerebrovascular complication
(s). Anastomotic insufficiency was categorised as 1) no complications, 2) complications other
than anastomotic insufficiency or 3) anastomotic insufficiency (as defined above).
Outcome
Three outcome variables were assessed from the Patient Registry: 1) total number of days of in-
hospitalisation, 2) number of hospitalisations, and 3) number of outpatient visits to a specialist
clinic. The study period was categorised into two periods: 1) the first year after surgery, exclud-
ing the oesophagectomy hospitalisation, and 2) the period from 1 year up to 5 years after oeso-
phagectomy. Indications for hospitalisations or outpatient visits were not taken into account.
Oesophageal Cancer and Healthcare-Utilisation
PLOS ONE | DOI:10.1371/journal.pone.0121080 March 13, 2015 3 / 10
Confounding
Possible confounders that were taken into account in the statistical models were: 1) age (cate-
gorised into 3 groups:<60, 60–74, or75 years), 2) sex, 3) comorbidity (3 groups: 0, 1,>1; in-
cluding hypertension, angina pectoris, heart failure, chronic obstructive pulmonary disease/
emphysema, asthma, diabetes, smoking, kidney diseases, liver diseases, other cancers and other
diseases), 4) tumour stage (4 groups: 0-I, II, III or IV, according to 6th edition of the TNM clas-
sification[17]), 5) histological type of tumour (2 groups: adenocarcinoma or squamous cell car-
cinoma), 6) annual hospital volume of oesophagectomies (2 groups:<15 or15
oesophagectomies per year),[18] and 7) neoadjuvant therapy (2 groups: yes or no).
Statistical analysis
Quasi-Poisson models were used to measure associations between the exposure and outcome
variables. Such models took over-dispersion into account and adjusted for all above mentioned
confounders. These models were used to account for the fact that events in this study did not
occur independently as assumed in conventional Poisson models, but were clustered within in-
dividual patients and within groups of patients. We used log(number of days at risk) as an off-
set in the models. The risk estimates were expressed as incidence rate ratios (IRR) and 95%
confidence intervals (95% CIs). There was a low number of missing values (n = 2 (0.5%), in
one covariate) which was unlikely to influence modelling results; hence we opted for a com-
plete case analysis. The baseline in these models was a patient with the following characteris-
tics: no complications, age younger than 60 years, male sex, no comorbidity, tumour stage 0-I,
adenocarcinoma, hospital volume of<15 oesophagectomies per year, and no neoadjuvant
therapy. Since patients who died during the study period had a shorter time at risk for the oc-
currence of events, we used an offset in the models. This is equivalent to using the event rate.
The hospitalisation for oesophagectomy was excluded from the analysis for all patients. All sta-
tistical analyses were performed using R.[19]
The unadjusted survival rates for each exposure group are visualized by means of a Kaplan
Meier curve.
Ethical considerations
All patients gave informed consent before inclusion in the study. The study was approved by
the Regional Ethical Review Board in Stockholm, Sweden.
Results
Patients
Characteristics of the 390 patients are presented in Table 1. There were 221 (57%) patients
without complications, 94 (24%) patients with one complication and 75 (19%) patients with
more than one complication. In total, 59 patients (15%) had a cardiovascular or cerebrovascu-
lar complication and 36 had an anastomotic insufficiency (9%). Relatively more complications
were seen in patients with several comorbidities and with early tumour stage. There were no
other major differences in baseline patient characteristics (Table 1). The survival time was lon-
ger for patients without complications, compared to patients with one or more than one com-
plication (Table 1, Fig. 1). The unadjusted healthcare utilisation in different patient groups,
showing minor differences only, is also presented in Table 1.
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Table 1. Patient characteristics among 390 patients treated with curatively intended oesophagectomy for cancer who survived for at least 1
year.
Number of complications* Total
0 1 >1
Total (N (%)) 221 (57) 94 (24) 75 (19) 390 (100)
Age (years)
<60 59 (27) 24 (26) 22 (29) 105 (27)
60–74 125 (57) 51 (54) 43 (57) 219 (56)
75 37 (17) 19 (20) 10 (13) 66 (17)
Sex
Male 173 (78) 77 (82) 62 (83) 312 (80)
Female 48 (22) 17 (18) 13 (17) 78 (20)
Comorbidities (number)
0 77 (35) 34 (36) 18 (24) 129 (33)
1 88 (40) 31 (33) 28 (37) 147 (38)
>1 56 (25) 29 (31) 29 (39) 114 (29)
Tumour stage^
0-I 43 (19) 22 (24) 25 (34) 90 (23)
II 81 (37) 34 (37) 18 (24) 133 (34)
III 86 (39) 28 (30) 23 (31) 137 (35)
IV 11 (5) 9 (10) 8 (11) 28 (7)
Histological type of tumour
Adenocarcinoma 170 (77) 75 (80) 52 (69) 297 (76)
Squamous cell carcinoma 51 (23) 19 (20) 23 (31) 93 (24)
Hospital volume
<15 oesophagectomies/year 145 (66) 60 (64) 52 (69) 257 (66)
15 oesophagectomies/year 76 (34) 34 (36) 23 (31) 133 (34)
Neoadjuvant therapy
Yes 25 (11) 12 (13) 6 (8) 43 (11)
No 196 (89) 82 (87) 69 (92) 347 (89)
Survival time in days
Median 747 516 378.5
Interquartile range 324–1826 267–1751 150–1231
Discharge to 1 year after oesophagectomy
Days of in-hospitalisation (interquartile range) 5 (0–16) 8 (0–20) 9 (0–25)
Number of hospitalisations (interquartile range) 1 (0–2) 1 (0–2) 1 (0–3)
Number of outpatient visits (interquartile range) 5 (3–9) 6 (4–10) 6 (3–10)
Year 1–5 after oesophagectomy
Days of in-hospitalisation (interquartile range) 16 (1–39) 14 (2–37) 15 (4–44)
Number of hospitalisations (interquartile range) 2 (1–4) 2 (1–4) 2 (1–4)
Number of outpatient visits (interquartile range) 6 (3–13) 6 (2–16) 8 (4–18)
^2 missing values.
*Only major complications causing clinical symptoms, as deﬁned in the method section are included.
doi:10.1371/journal.pone.0121080.t001
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Healthcare utilisation between discharge and one year after
oesophagectomy
There was an increased total number of days of in-hospitalisation in patients with more than 1
complication from discharge to one year after oesophagectomy, compared to patients without
complications (IRR 1.7, 95% CI 1.1–2.7) (Table 2). We found no association between number
of complications and number of hospitalisations (IRR 1.3, 95% CI 0.9–1.8) or number of out-
patient visits (IRR 1.2, 95% CI 1.0–1.4) (Table 2). The IRRs for patients with cardiovascular or
cerebrovascular complications, compared to patients without complications, were 1.4 (95% CI
0.8–2.2) for total number of days of in-hospitalisation, 1.1 (95% CI 0.7–1.6) for number of hos-
pitalisations, and 1.2 (95% CI 1.0–1.5) for number of outpatient visits (Table 2). The total
Fig 1. Kaplan Meier curve showing survival time in days by exposure group.
doi:10.1371/journal.pone.0121080.g001
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number of days of in-hospitalisation was increased in patients with anastomotic insufficiency
(IRR 2.0, 95% CI 1.1–3.4) (Table 2). The association with number of hospitalisations (IRR 1.4,
95% CI 0.9–2.2) and number of outpatient visits (IRR 1.3, 95% CI 1.0–1.6) for patients with
anastomotic insufficiency was limited (Table 2).
Healthcare utilisation 1–5 years after oesophagectomy
The total number of days of in-hospitalisation 1–5 years following oesophagectomy was higher
in patients with more than 1 complication (IRR 1.5, 95% CI 1.0–2.4). We found no association
between number of complications and number of hospitalisations (IRR 1.1, 95% CI 0.7–1.6) or
number of outpatient visits (IRR 1.2, 95% CI 0.9–1.6) (Table 2). Compared to patients without
complications, patients with cardiovascular or cerebrovascular complications had IRRs of 1.5
(95% CI 0.9–2.5) for total number of days of in-hospitalisation, 1.2 (95% CI 0.7–1.9) for num-
ber of hospitalisations, and 1.1 (95% CI 0.8–1.5) for number of outpatient visits. There was an
increased total number of days of in-hospitalisation in patients with anastomotic insufficiency
(IRR 1.8, 95% CI 1.0–3.0) (Table 2), but no associations with number of hospitalisations (IRR
1.2, 95% CI 0.7–2.0) or number of outpatient visits (IRR 1.3, 95% CI 0.9–1.7) after these com-
plications (Table 2).
Discussion and Conclusion
This study indicates a long-lasting increase of healthcare utilisation, especially for total dura-
tion of in-hospitalisation, among patients who suffer from a major complication shortly after
oesophagectomy for cancer, particularly among patients with anastomotic insufficiency.
Strengths of this study include the prospective and population-based design with high par-
ticipation rate with long and complete follow-up of the patients. Moreover, the information on
Table 2. Healthcare utilisation in relation to major postoperative complications, cardiovascular or cerebrovascular complications and
anastomotic insufﬁciency among 390 patients treated with curatively intended oesophagectomy for cancer who survived at least 1 year.
< 1 year of oesophagectomy  1 year to 5 years of oesophagectomy
Inpatient Outpatient Inpatient Outpatient
Days of in-
hospitalisation
Number of
hospitalisations
Number of
outpatient visits
Days of in-
hospitalisation
Number of
hospitalisations
Number of
outpatient visits
IRR 95%-CI IRR 95%-CI IRR 95%-CI IRR 95%-CI IRR 95%-CI IRR 95%-CI
Complications
No complications 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
1 complication 1.3 (0.9–2.1) 1.3 (0.9–1.7) 1.1 (0.9–1.3) 1.3 (0.8–2.0) 1.2 (0.8–1.8) 1.1 (0.9–1.5)
>1 complication 1.7 (1.1–2.7) 1.3 (0.9–1.8) 1.2 (1.0–1.4) 1.5 (1.0–2.4) 1.1 (0.7–1.6) 1.2 (0.9–1.6)
Complications other than
cardiovascular or cerebrovascular
complications
1.6 (1.1–2.4) 1.4 (1.0–1.9) 1.1 (0.9–1.3) 1.3 (0.9–2.0) 1.2 (0.8–1.7) 1.2 (0.9–1.5)
Cardiovascular or cerebrovascular
complication(s)
1.4 (0.8–2.2) 1.1 (0.7–1.6) 1.2 (1.0–1.5) 1.5 (0.9–2.5) 1.2 (0.7–1.9) 1.1 (0.8–1.5)
Complications other than
anastomotic insufﬁciency
1.4 (0.9–2.1) 1.2 (0.9–1.7) 1.1 (0.9–1.3) 1.3 (0.9–1.8) 1.2 (0.8–1.6) 1.1 (0.9–1.4)
Anastomotic insufﬁciency 2.0 (1.1–3.4) 1.4 (0.9–2.2) 1.3 (1.0–1.6) 1.8 (1.0–3.0) 1.2 (0.7–2.0) 1.3 (0.9–1.7)
Adjusted incidence rate ratios* (IRR) with 95% conﬁdence intervals (CI) are presented.
*Results were adjusted for age, sex, tumour stage, comorbidity, histological type of tumour, hospital volume and neoadjuvant therapy.
doi:10.1371/journal.pone.0121080.t002
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complications was comprehensive and based on clear definitions formulated before the initia-
tion of the data collection, and the assessment of both the inpatient and outpatient healthcare
utilisation was objective and accurate, ensuring high validity of both exposure and outcome
measures. Our used outcome measures, number of hospitalisations, hospitalisation days and
number of outpatient visits, are frequently used proxies of healthcare utilisation costs since
these also enable comparison between countries with other healthcare and reimbursement sys-
tems. Also, the results were adjusted for all major prognostic factors, although residual con-
founding cannot be excluded in observational research. By using quasi-Poisson models, we
took overdispersion into account to assess for potential clustering. Although we could have
used several other statistical models for the analyses, more complex models such as generalised
estimation equation models (GEEs) showed very similar results.
Among weaknesses was the limited statistical power to detect weak differences between
groups. Yet, the study included virtually all eligible patients in Sweden (limiting the risk of se-
lection bias), and moderately strong associations were found. At the time this study was con-
ducted (2001–2005), there was insufficient evidence for the efficacy of neoadjuvant or adjuvant
oncological therapy in patients operated for oesophageal cancer with curative intent, and thus
this therapy was not used in Sweden during the study period. Only a small proportion of pa-
tients received neoadjuvant treatment, which was not current practice for patients operated for
oesophageal cancer at that time in Sweden. Although we corrected for potential confounding
by neoadjuvant therapy, our findings may differ from cohorts receiving other neoadjuvant or
adjuvant treatment regimens. Other scoring systems for complications were not available at
the time for initiating the present cohort, for example including different levels of severity.[20].
However, we chose to only include major complications considered relevant for this type of
surgery, as defined before the data-collection by a board of Swedish oesophageal surgeons.
[14,16] Post-hoc comparison with the Accordion Severity Grading System shows that our defi-
nitions of complications would most likely fall within the categories 3–5 (“Severe”), although it
was not always possible to align these definitions.[21] The classification of comorbidities was
decided upon in a similar manner and does not enable post-hoc re-categorisation to other co-
morbidity scores such as the Charlson comorbidity index,[22] using slightly other categories,
definitions and additional comorbidities which were not collected as such in the present study.
However, since comorbidities are only examined as confounders and not as exposures, the im-
pact of the used categorisation was considered limited. Another potential weakness was that we
did not restrict our analyses to cancer-specific healthcare utilisation. Distinguishing cancer-
specific and other healthcare utilisation is not always straight forward. Overall health may re-
main worse compared to the general population as a consequence of the cancer or treatment,
consequently indirectly increasing primary and specialised health care utilisation.[23,24] There
was little difference in presence of comorbidities between patients without complication and
patients with one complication, but approximately 10% more comorbidities were found in the
group with more than one complication. However, the amount of non-cancer related special-
ised medical healthcare utilisation, in particular hospitalisations, is assumed to be rather similar
in the comparison groups of patients. Thus, any misclassification of the outcome was likely to
be non-differential, and would therefore rather dilute the associations between the complica-
tions and healthcare utilisation, which would indicate that the true associations might
be stronger.
To the best of our knowledge, this is the first study that has explored the relation between
postoperative complications and long-term healthcare utilisation after oesophagectomy. Overall,
we found an increase in healthcare utilisation in relation to postoperative complications in the
long-term after oesophagectomy, at least regarding the total number of days of in-hospitalisation.
Healthcare utilisation was particularly associated with an increase in patients with anastomotic
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insufficiency. However, other factors, such as tumour stage and treatment-related factors may
also influence the risk of complications and long-term healthcare utilisation. Since these out-
comes have been investigated only for this cohort, more studies are necessary to confirm
the findings.
In conclusion, this population-based and prospective cohort study indicates that early
major complications following oesophagectomy for cancer may be associated with long-term
healthcare utilisation, as indicated by an increased total in-hospitalisation period, especially in
patients who have had anastomotic insufficiency.
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